Varna

• Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis Not authorised
  2023-503634-50-00 5 Anemia in patients with chronic kidney disease on dialysis
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavaila … Pending
  2023-508981-13-00 2 Schizophrenia
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 5 Agitation Associated with Alzheimer’s Disease
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A Study to Compare the Effectiveness and Safety of T1695 (0.1% Tacrolimus) Versus Ciclosporin in Participants With Moderate to Severe Vernal … Pending
  2025-521567-12-00 4 Vernal Keratoconjunctivitis (VKC)
• A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gr … Pending
  2025-522406-20-00 9 Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE … Pending
  2025-522775-29-00 5 Depressive episodes associated with Bipolar disorder I or II (Bipolar
• An Open-label Study of Azetukalner in Bipolar I or II Depression Pending
  2025-522872-10-00 5 Depressive episodes associated with Bipolar disorder I or II (Bipolar
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 5 Obesity
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Pending
  2025-523511-11-00 5 Obesity
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 5 Chronic Spontaneous Urticaria
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting
  2024-520446-31-00 5 2026-05-27 Participants with overweight or obesity, and type 2 diabetes
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521711-39-00 5 2026-05-17 Lewy body Dementia psychosis (LBDP)
• A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have … Recruiting
  2025-521730-28-00 4 2026-03-30 Colorectal Cancer with Cancer Cachexia
• Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus. Recruiting
  2025-522729-36-00 7 2026-03-11 Chronic Hepatitis Delta.
• Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting
  2024-519836-18-00 5 2025-12-16 treatment-resistant schizophrenia (TRS)
• A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting
  2024-519343-15-00 5 2025-10-08 Low-grade Upper Tract Urothelial Cancer
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici … Recruiting
  2024-516792-32-01 4 2025-07-18 Metastatic non-squamous non-small cell lung cancer

Showing 1–24 of 158 trials